Company / Revenue per Share
Arrowhead Pharmaceuticals Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$6.67
FY2025
5-year range
$0.03 / $6.67
FY2021-FY2025
Trend
+20053.5%
vs FY2024
Sector context
#59 of 154
Health Care
What the data says
Revenue per Share changed +20053% YoY in FY2025, a notable deviation from the 9-year average annual change of +4098%.
Based on SEC 10-K filings.
6.67 in FY2025 with a 5-year CAGR of +48.6%.
Improved from $1.31 to $6.67 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +99.2%
- 5-Year CAGR
- +48.6%
- 10-Year CAGR
- -
Sector benchmark
#59 of 154 in Health CareTop 38% of 154This company $6.67 Sector average $15.09
▼
-55.8% below sector average
Key checks
Key Insights
- In FY2025, revenue per share increased 20053.5% year-over-year.
- Ranks #59 out of 154 companies in the Health Care sector.
- Lowest revenue per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.67 | +20053.5% |
| FY2024 | $0.03 | -97.5% |
| FY2023 | $1.31 | +54.7% |
| FY2022 | $0.84 | -37.6% |
| FY2021 | $1.35 | +46.6% |
| FY2020 | $0.92 | +159.6% |
| FY2019 | $0.35 | +16661.6% |
| FY2018 | $0.00 | -61.3% |
| FY2017 | $0.01 | +106.0% |
| FY2016 | $0.00 | -49.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026